Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company has a collaboration agreement with Navigo Proteins GmbH for the advancement of affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RGEN
CUSIP75991610
Phone781-250-0111
Debt
Debt-to-Equity RatioN/A
Current Ratio2.09
Quick Ratio1.75
Price-To-Earnings
Trailing P/E Ratio71.77
Forward P/E Ratio69.75
P/E Growth3.27
Sales & Book Value
Annual Sales$141.24 million
Price / Sales15.36
Cash Flow$0.8692 per share
Price / Cash56.97
Book Value$13.58 per share
Price / Book3.65
Profitability
EPS (Most Recent Fiscal Year)$0.69
Net Income$28.35 million
Net Margins13.49%
Return on Equity5.05%
Return on Assets4.02%
Miscellaneous
Employees476
Outstanding Shares43,810,000
Market Cap$2.16 billion
Repligen (NASDAQ:RGEN) Frequently Asked Questions
What is Repligen's stock symbol?
Repligen trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen's earnings last quarter?
Repligen Co. (NASDAQ:RGEN) issued its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported $0.16 EPS for the quarter, missing the Zacks' consensus estimate of $0.18 by $0.02. The biotechnology company had revenue of $47.73 million for the quarter, compared to analysts' expectations of $45.84 million. Repligen had a net margin of 13.49% and a return on equity of 5.05%. The business's revenue was up 47.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.20 earnings per share. View Repligen's Earnings History.
When is Repligen's next earnings date?
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share guidance of $0.69-0.73 for the period, compared to the Thomson Reuters consensus estimate of $0.70. The company issued revenue guidance of $185-190 million, compared to the consensus revenue estimate of $185.40 million.
What price target have analysts set for RGEN?
6 analysts have issued 12-month price targets for Repligen's stock. Their forecasts range from $40.00 to $56.00. On average, they expect Repligen's stock price to reach $46.8333 in the next twelve months. This suggests that the stock has a possible downside of 5.4%. View Analyst Price Targets for Repligen.
What is the consensus analysts' recommendation for Repligen?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen.
Who are some of Repligen's key competitors?
Some companies that are related to Repligen include bluebird bio (BLUE), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY) and Atara Biotherapeutics (ATRA).
Who are Repligen's key executives?
Repligen's management team includes the folowing people:
- Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 54)
- Mr. Jon K. Snodgres, CFO & Sec. (Age 52)
- Mr. Steve Curran, VP of Global Operations
- Ms. Sondra S. Newman, Sr. Director of Investor Relations
- Mr. Stephen Tingley, VP of Sales
Has Repligen been receiving favorable news coverage?
News coverage about RGEN stock has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Repligen earned a news impact score of 0.16 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.55 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Repligen.
Who are Repligen's major shareholders?
Repligen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.36%), OppenheimerFunds Inc. (4.88%), Conestoga Capital Advisors LLC (3.92%), Macquarie Group Ltd. (2.53%), Dimensional Fund Advisors LP (2.32%) and Stephens Investment Management Group LLC (2.09%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.
Which institutional investors are selling Repligen stock?
RGEN stock was sold by a variety of institutional investors in the last quarter, including Wolverine Asset Management LLC, Federated Investors Inc. PA, Pier Capital LLC, California Public Employees Retirement System, Summit Creek Advisors LLC, Stephens Investment Management Group LLC, ClariVest Asset Management LLC and Kornitzer Capital Management Inc. KS. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Howard Benjamin, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.
Which institutional investors are buying Repligen stock?
RGEN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Fred Alger Management Inc., Jennison Associates LLC, Redwood Investments LLC, OppenheimerFunds Inc., Macquarie Group Ltd., Conestoga Capital Advisors LLC and Tygh Capital Management Inc.. View Insider Buying and Selling for Repligen.
How do I buy shares of Repligen?
Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen's stock price today?
One share of RGEN stock can currently be purchased for approximately $49.52.
How big of a company is Repligen?
Repligen has a market capitalization of $2.16 billion and generates $141.24 million in revenue each year. The biotechnology company earns $28.35 million in net income (profit) each year or $0.69 on an earnings per share basis. Repligen employs 476 workers across the globe.
How can I contact Repligen?
Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]
MarketBeat Community Rating for Repligen (NASDAQ RGEN)
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
